Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

Apr 17 2024

• By Andrew McConaghie

Precision Biosciences

Related Content

Sarepta Confident Of Full US Approval For Duchenne Gene Therapy By Mid-2024

Jan 09 2024

Allo CAR-T Is Still On The Shelf As Precision Moves On

Aug 16 2023

Related Companies

Eli Lilly and Company

Precision BioSciences, Inc.

Sarepta Therapeutics, Inc.

CRISPR Therapeutics AG

Vertex Pharmaceuticals Incorporated

Novartis AG

Additional Topics

Deals Companies Gene Therapy Research & Development Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window